As we reimagine the future of longevity insurance underwriting and support the growth of global longevity markets with a next-generation underwriting protocol, we seek to discover and understand the role epigenetic biomarkers play in individual health, wellness, and aging in order to empower people to improve the length and quality of their lives, and make more informed choices that benefit their health.
While a person’s underlying genetic code is stable throughout life, their health, wellness and aging leave discernible marks on the genome that modify how genes are expressed. The epigenome is the combination of all such natural modifications; while epigenetic modifications can register within seconds to minutes, they can imprint signatures on the epigenome for decades, leaving a unique biography of an individual’s health and wellness history.
How We Do It
To identify epigenetic biomarkers along the epigenome, we apply advanced supervised machine learning and artificial intelligence technologies to create predictive models that correlate epigenetic profiles with states of health, wellness, disease, and aging. Our high throughput, CLIA-certified laboratories also support human and mouse epigenetic methylation testing for the scientific research community.
Who We Serve
As a molecular biotechnology company, we are developing innovative new products and epigenetic testing services that provide cost-effective solutions for the scientific research community.
We are using epigenetics to reimagine the future of life insurance with a next-generation underwriting protocol and consumer engagement platform focused on improving human health and lifespan.
Follow our CEO, Jon Sabes’ approach to longevity and legacy.
Follow along on our journey to transform the global longevity insurance industry.
You may unsubscribe whenever you wish.